ICOTYDE Janssen-Cilag Pty Ltd
Product name
ICOTYDE
Sponsor
Accepted date
Jan-2026
Active ingredients
icotrokinra
Proposed indication
ICOTYDE (icotrokinra) is proposed as a treatment of moderate to severe plaque psoriasis in adults and paediatric patients 12 years of age and older who are candidates for systemic therapy or phototherapy
Application type
A (new medicine)
Publication date
Jan-2026